Double attack on cancer: engineered immune cells plus drug trial offers hope for tough lymphoma cases
NCT ID NCT04484012
Summary
This study tests whether combining two treatments works better against mantle cell lymphoma that has returned or resisted previous therapies. Researchers modify patients' own immune cells to target cancer and give them with the drug acalabrutinib. The trial aims to see if this combination is safe and can eliminate cancer in more patients. About 36 adults who have already tried other treatments may participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.